List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. AI-enabled fully automated retinal image-based biomarkers for mild cognitive impairment and neurodegenerative disorders

    SBC: EYENUK, INC.            Topic: NINDS

    AbstractIn this SBIR projectwe present EyeQuantan AI enabled fully automated tool to compute retinal image based biomarkers for mild cognitive impairment and neurodegenerative disordersThe largegrowingand aging population is likely to lead to a dramatic increase in the number of people at risk for dementia and other cognitive disorderswith more thanmillion people expected to be affected byVascular ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy

    SBC: Aptitude Medical Systems, Inc.            Topic: NEI

    Abstract SignificanceProliferative vitreoretinopathyPVRis a blinding orphan indication that occurs inof patients receiving rhegmatogenous retinal reattachment surgeryand accounts forof all primary surgical failuresPVR is characterized by migration and proliferation of ectopic cells beneath or on the surface of the retinawhich then assemble into a membranecausing retinal traction and detachmentSinc ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels

    SBC: NAVEGA THERAPEUTICS, INC.            Topic: 102

    Project Summary Abstract The goal of this project is to develop a therapeutic product that relieves chemotherapy induced peripheral neuropathyCIPNin a non permanentnon addictive and long lasting manner to improve the quality of life of cancer patientsCurrently more thanmillion Americans andbillion people worldwide suffer from chronic painVoltage gated sodium channels transmit pain signals in nocic ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Discovery of new therapeutics for Huntingtons Disease through successive reversal of phenotypic signatures

    SBC: Rumi Scientific, Inc.            Topic: NINDS

    Summary Huntingtonandapos s diseaseHDis a dominant autosomal neurodegenerative disease that is caused by an expansion of CAG repeats in the HTT locus that translates into an increase of poly glutaminepolyQrepeat in the Huntingtin protein HTTIt is estimated thatinAmericans suffer from HDDespite the fact that HTT was among the first disease causing genes to be cloned overyears agono therapy yet exis ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Biosensor and Eyedrop Bottle Technologies for Glaucoma Adherence Monitoring

    SBC: Toromedes, Inc            Topic: NEI

    Project SummaryNon adherence with prescribed systemic drugs leads to poor outcomes and increases the cost of healthcareGlaucomathe leading cause of irreversible blindnessaffects more thanmillion people worldwideLowering intraocular pressurethe only proven method of delaying both the development and progression of glaucomais typically done with topical administration of eye dropswhich has notorious ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of An Oral,Brain/Eye penetrating, Second Generation TTR Stabilizer for The Treatment of Transthyretin Amyloidoses

    SBC: PROTEGO BIOPHARMA, INC.            Topic: NINDS

    The TTR AmyloidosesATTRare rareprogressiveultimately fatal diseases that compromise the function of multiple organscausing a wide range of debilitating clinical symptomsATTR is caused by the dissociation of the tetrameric transthyretinTTRproteinleading to misfolding and aggregation of the released monomers with toxic oligomer formation and subsequent tissue deposition as physiologically insoluble ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a biomimetic small molecule therapeutic for neovascular retinal diseases

    SBC: EyeMedix, Inc.            Topic: NEI

    PROJECT SUMMARYABSTRACTRetinal diseasesincluding age related macular degenerationAMDand diabetic retinopathyDRare the leading causes of vision loss and blindness in people overyears oldAccording to the NEIinnearlymillion people in the U Ssuffered from some form of these diseaseswhose prevalence is expected to increase tomillion overyearsRecently approved therapies have focused on the exudativewetf ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain

    SBC: Peptide Logic LLC            Topic: NIDA

    PROJECT SUMMARY ABSTRACT The proposed SBIR Phase II program seeks to select a first in classperipherally restrictedand long acting somatostatin receptorLA SSTRagonist clinical candidate for development as a novel non addictive analgesic able to replace opioids for the treatment of moderate to severe chronic painThe program is based on strong scientific evidence showing that activation of periphera ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain

    SBC: Adynxx, Inc.            Topic: NINDS

    RESEARCH AND RELATED OTHER PROJECT INFORMATIONPROJECT SUMMARYABSTRACTFunding OpportunityPAPI NameMametJulienAs described by the HEAL Initiative Notice NOT NSthere currently exists an urgent unmet need for enhanced pain management in the form of safeeffectivenon opioid pain treatmentsChronic focal neuropathic painwhich includes pain etiologies such as radiculopathy and radiculitisfocal peripheral n ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Repression of Sodium Channels via a Gene Therapy for Treatment of Chronic Neuropathic Pain

    SBC: NAVEGA THERAPEUTICS, INC.            Topic: NINDS

    Project Summary Abstract Currently more thanmillion Americans andbillion people worldwide suffer from chronic painThis is more than cancerdiabetesand heart disease combinedVoltage gated sodium channels are responsible for the transmission of pain signalsNine genes have been identifiedeach having unique properties and tissue distribution patternsGenetic studies have correlated a hereditary loss of ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government